Equities

Unichem Laboratories Ltd

UNICHEMLAB:NSI

Unichem Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)877.05
  • Today's Change3.85 / 0.44%
  • Shares traded38.44k
  • 1 Year change+113.91%
  • Beta0.1865
Data delayed at least 15 minutes, as of Nov 12 2024 10:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Unichem Laboratories Ltd grew revenues 26.94% from 13.43bn to 17.05bn. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -2.02bn to -704.74m.
Gross margin62.00%
Net profit margin-3.50%
Operating margin-3.35%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Unichem Laboratories Ltd fell by 328.40m. However, Cash Flow from Investing totalled 504.04m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 166.94m in cash from operations while cash used for financing totalled 1.06bn.
Cash flow per share7.41
Price/Cash flow per share119.11
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Unichem Laboratories Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 65.15%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
66.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.